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Background. Cell therapy for heart disease has been proven safe and eﬃcacious, despite poor cell retention in the injected area.
Improving cell retention is hypothesized to increase the treatment eﬀect. In the present study, human adipose-derived stromal
cells (ASCs) were delivered in an in situ forming alginate hydrogel following acute myocardial infarction (AMI) in rats.
Methods. ASCs were transduced with luciferase and tested for ASC phenotype. AMI was inducted in nude rats, with subsequent
injection of saline (controls), 1× 106 ASCs in saline or 1× 106 ASCs in 1% (w/v) alginate hydrogel. ASCs were tracked by
bioluminescence and functional measurements were assessed by magnetic resonance imaging (MRI) and 82rubidium positron
emission tomography (PET). Results. ASCs in both saline and alginate hydrogel signiﬁcantly increased the ejection fraction
(7.2% and 7.8% at 14 days and 7.2% and 8.0% at 28 days, resp.). After 28 days, there was a tendency for decreased infarct area
and increased perfusion, compared to controls. No signiﬁcant diﬀerences were observed between ASCs in saline or alginate
hydrogel, in terms of retention and functional salvage. Conclusion. ASCs improved the myocardial function after AMI, but
administration in the alginate hydrogel did not further improve retention of the cells or myocardial function.
1. Introduction
The leading cause of death in the world is cardiovascular
disease. Approximately one million people suﬀer myocardial
infarction (MI) each year in the USA alone. Despite great
improvements in treatment of these patients, an increasing
group of patients still suﬀer from heart failure [1].
Within the past two decades, cellular therapy using
mesenchymal stromal cells (MSCs) for treating heart disease
has been proven safe and able to moderately enhance the
function of the heart [2, 3]. MSCs can be obtained from
almost every tissue in the body, but most studies have used
adipose-derived MSCs (ASCs) or bone marrow MSCs [4].
The eﬀect of the treatment is attributed to the paracrine
potential of the MSCs [5, 6]. MSCs are capable of adapting
their secretome to meet the needs of their surroundings.
The abilities to modify immune responses, initiate angio-
genesis, and provide trophic factors for damaged native
cells make MSCs a perfect candidate for the treatment of
myocardial infarction [6]. However, the administered MSCs
are only present in the heart for a brief period of time, with
evidence for 10% retention after 24 hours, and declining
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retention in the following weeks [7–9]. Increasing the
retention of the transplanted cells using various methods
has resulted in increased functional gain compared to the
regular treatment in preclinical models [10]. Many of the
applied methods to increase cell retention are more explor-
atory than directly translatable into the clinic. As such, the
reliance on modiﬁcation of the MSCs or the coinjection of
complicated synthetic scaﬀolds makes the translation more
diﬃcult [11]. For clinical application, the cell product must
be minimally modiﬁed from their original phenotype, and
every modiﬁcation to scaﬀolds or hydrogels makes the regu-
latory process much more diﬃcult. As the most translatable
choice for administration, we investigated an in situ formed
alginate hydrogel formulation currently in clinical trials
as monotherapy for acute myocardial infarction (AMI)
[12–14]. The unique features of this hydrogel are due to
the fabrication as a ﬂowable cross-linked alginate network,
which undergoes gelation into a hydrogel at the presence
of the Ca2+ ion concentrations available at the infarcted
heart [15].
We have previously demonstrated that ASCs maintained
high viability during culture in this alginate hydrogel, and
that ASCs modify their phenotype and exhibit increased
paracrine immunomodulatory function while embedded in
the alginate hydrogel [16, 17].
In the present study, we investigated whether injecting
transduced ASCs in an in situ formed alginate hydrogel
would increase the retention of the cells and improve
myocardial function in rats after AMI.
To do so, we tracked the ASCs by bioluminescence
(BLI), used cardiac magnetic resonance imaging (MRI)
to assess heart volumes and pumping function, and used
82rubidiumpositron emission tomography/computed tomog-
raphy (82Rb-PET/CT) to assess the perfusion of the heart.
To the best of our knowledge, we are the ﬁrst to apply
82Rb-PET/CT in a small animal model to assess the eﬀect
of treatment in myocardial infarction.
2. Methods
2.1. Experimental Design. Human ASCs were transduced to
express luciferase and characterized in vitro. An experi-
mental model for acute myocardial infarction (AMI) in
rats was established with injection of saline (control), ASCs
in saline, or ASCs in alginate hydrogel immediately following
infarction. The functional measurements were obtained with
cardiac magnetic resonance imaging (MRI) and 82rubidium-
PET/CT (82Rb-PET/CT) on days 1, 14, and 28 after the
operation. Cell tracking by bioluminescence imaging (BLI)
was performed at days 1, 3, 7, 14, and 21 after treatment
(Figure 1). Treatment was randomized, and outcome assess-
ment was blinded.
2.2. Cell Culture. Lipoaspirate was harvested from two
healthy human donors (females, aged 37 and 55 years). The
use of the lipoaspirate was approved by the National Ethical
Committee protocol number H-3-2009-119 and informed
written consent was signed by the donors.
ASCs were isolated from the lipoaspirate, as described
elsewhere [18]. Brieﬂy, the lipoaspirate was washed twice
with phosphate-buﬀered saline (PBS) (Gibco, Life Technolo-
gies) before being digested with 0.6 PZU/ml collagenase
NB 4 (Serva) dissolved in Hank’s balanced salt solution
(2mmol/l Ca2+, Thermo Fisher Scientiﬁc) for 45–55min,
while incubated at 37°C at constant rotation. Collagenase
was inactivated by addition of fetal bovine serum (FBS)
medium (minimum essential medium alpha modulation
(αMEM), 1% penicillin/streptomycin, and 10% irradiated
FBS (all from Gibco, Thermo Fisher Scientiﬁc)). The sus-
pension was centrifuged, and the mononuclear cells were
counted on a NucleoCounter NC-100 (ChemoMetec),
seeded in a density of 4.5× 106 cells/T75 ﬂask (Thermo
Fisher Scientiﬁc) in FBS medium, and incubated in standard
conditions at 37°C, 5% CO2, and 21% O2 with humidiﬁed air.
After three days of culture, the medium was removed, and
the ﬂasks were washed with PBS for the removal of nonad-
herent cells. Medium was changed twice a week, until
conﬂuence was reached and the cells were washed with
PBS, detached with 3ml TrypLE Select (Gibco, Life Technol-
ogies), and centrifuged at 300g for 5min. After an additional
culture passage, the ASCs were counted and frozen in liquid
nitrogen in a density of 1× 106 cells/ml in 10% dimethylsulf-
oxide (WAK-Chemia Medical), 90% FBS.
2.3. Labeling. The L2T plasmid was supplied by Professor
Gambhir, Stanford University, and a detailed description of
the plasmid can be found elsewhere [19]. Brieﬂy, the L2T
plasmid consists of a ﬁreﬂy luciferase 2 sequence connected
MI and treatment
Tracking by bioluminescence
Volumes by cardiac MRI and perfusion by 82rubidium-PET/CT
Histology
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Figure 1: Experimental setup. Myocardial infarction was induced and rats were treated with either saline, ASCs in saline, or ASCs in alginate
hydrogel on day 0. The ASCs were tracked at days 1, 3, 7, 14, and 21 after administration, with a subgroup being tracked 6 hours after
injection. Functional measurements were obtained using cardiac magnetic resonance imaging (cardiac MRI) and rubidium-82 positron
emission tomography/computer tomography (82Rb-PET/CT) at days 1, 14, and 28 postoperation.
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by a short linker to a td tomato sequence, with a ubiquitin
promotor and zeocin resistance.
The L2T plasmid was propagated in bacteriophages. For
packaging of the plasmid in lentiviral particles, HEK293T
cells were seeded on day 1 in Dulbecco’s modiﬁed Eagle’s
medium (DMEM), 10% fetal calf serum (AUS sourced, In
Vitro Technologies), glutamine, and penicillin/streptomycin.
On day 2, the HEK293T cells were transfected using CaPO4
transfection with the pFUG L2T vector and the two helper
plasmids PDMG.2 and 8.91 (both from Didier Tromo Lab.,
Geneva), responsible for envelope and packaging, respec-
tively. The transfection on day 2 was performed in 10%
CO2, with conditions being changed to 3% CO2 until day 3.
At the third day, the medium was changed and the incuba-
tion continued in 5% CO2. Medium was collected at day 5,
ﬁltered through a 0.45μl ﬁlter and concentrated 20 times
using Vivaspin ﬁlter (cutoﬀ 100.00 MW).
The transduction with the lentiviral particles was per-
formed with 30.000 ASCs in each well in 6-well plates in
FBS medium containing a titer of 25mg virus per well
and polybrene. After two days of quarantine, the trans-
duced ASCs were transferred to T75 ﬂasks and culture
expanded in human platelet lysate (hPL) medium (αMEM,
1% penicillin/streptomycin, and 5% Cook Regentec Stemu-
late). The L2T-ASCs were expanded for one passage before
being sorted by tdTomato expression, using a FACSJazz
ﬂow cytometry-activated cell sorter (BD Bioscience) at
the Flow Cytometry Core Facility at the University of
Copenhagen. The L2T-transduced ASCs were subsequently
expanded for two passages, completing a total of 5 passages
from their original isolation from the stromal vascular
fraction, before being frozen, as described earlier [20].
Two to three weeks before the transduced ASCs were
injected in the animals, they were thawed and cultured in
hPL culture medium in T75 ﬂasks at standard incubation
conditions. Hence, the treated rats received L2T-ASCs
in passage 7-8.
2.4. Characterization of L2T-Transduced ASCs
2.4.1. Surface Marker Expression. The surface marker expres-
sion of the transduced ASCs was characterized by ﬂow
cytometry. The following antibodies (all purchased from
BD Biosciences) were used: CD105-Brilliant Violet-421
(BV421) (clone 266), CD90-allophycocyanin (APC) (5E10),
CD73-APC (AD2), CD13-phycoerythrin-cyanin 7 (PE-Cy7)
(WM15), CD45-ﬂuorescein isothiocyanate (FITC) (2D1),
CD34-APC (581), and HLA-DR, DP, DQ-BV421 (Tu39).
Fixable, viable stain 780 (FVS780) (cat. number 565388)
was used to discriminate live from dead cells. Upon harvest,
the cells were washed in PBS twice and stained with
FVS780 for 10min. Subsequently, the cells were washed
in FACS PBS (Hospital Pharmacy) containing 1% ethylene-
diaminetetraacetic acid (EDTA) (Hospital Pharmacy) and
10% newborn calf serum (Gibco, Thermo Fisher Scientiﬁc)
and stained for 30min at room temperature, protected
from light. Finally, the cells were washed in FACS PBS
and resuspended in PBS. At least 4000 cells were measured
on a Navios ﬂow cytometer and analyzed using Kaluza
software version 1.5a (both Beckman Coulter). Debris,
doublets, and dead cells were excluded from the analysis.
2.4.2. Triple Diﬀerentiation. The transduced ASCs were tri-
ple diﬀerentiated using StemPro diﬀerentiation kit (Gibco,
Thermo Fisher Scientiﬁc) according to manufacturer’s
instructions. Adipogenic diﬀerentiation was veriﬁed by oil
red O (Sigma-Aldrich) staining lipid droplets, osteogenic
diﬀerentiation by alizarin red S for calcium deposits, and
chondrogenic diﬀerentiation by alcian blue 8GX (Sigma-
Aldrich) for glycosaminoglycans.
2.4.3. β-Galactosidase Staining. To assess if the whole process
of generating the transduced ASCs resulted in the cells being
senescent, the endogenous β-galactosidase activity was inves-
tigated using the β-gal staining kit (Thermo Fisher Scientiﬁc)
according to manufacturer’s protocol. X-Gal was prepared
fresh in N,N-dimethylformamide (Sigma-Aldrich Chemie
GmbH) for staining solution. Cells were incubated for 24
hours at standard incubation conditions, and the staining
was observed using an IX51 microscope (Olympus).
2.5. Alginate Hydrogel Casting. A 2.6% alginate solution
(VLVG sodium alginate, NovaMatrix, FMC Biopolymers)
was made in sterile water and partially cross-linked with a
solution of 3% calcium gluconate (D-gluconic acid hemi-
calcium salt, Sigma-Aldrich) [21]. This mixture was subse-
quently diluted to a 1% w/v alginate and 0.3 calcium
gluconate solution with sterile water. Prior to administra-
tion, a centrifuged cell pellet was resuspended in the
alginate solution.
2.6. Animals. For this study, 97 athymic nude rats
(Crl : Foxn1rnu) were included. The athymic nude rat was
chosen based on evidence of lower levels of macrophage inﬁl-
tration in the heart and improved long-term graft retention
compared to other strains [9, 22]. All animal experiments
were approved by the Danish Animal Experiments Inspec-
torate (permit number 2012-15-2934-00064 and 2016-15-
0201-00920). The animals were housed in the core animal
facilities at the University of Copenhagen, Denmark, with
12 : 12 hours light/dark cycle, at 21± 2°C, and access to water
and rodent food ad libitum. The animals were acclimatized
for at least one week before being included in the experi-
ments. In order to test a cell product as close to the clinic as
possible, we chose human ASCs as xenografts in athymic
nude rats.
2.7. MI Induction and Treatment. The myocardial infarctions
were induced as described elsewhere [23]. In brief, the
animals were anesthetized in 3–5% sevoﬂurane (AbbVie,
Denmark) in an induction chamber before being intubated
with a 16G Venﬂon catheter (Vasoﬁx® Safety, Braun,
Denmark) with blunt needle and ventilated with 6–8ml air/
ventilation, at a frequency 80–90 ventilations/min (UNO
microventilator-03, Netherlands). The animals were injected
subcutaneously with 0.05mg/kg buprenorphine (Temgesic®,
Indivior, UK) and 1ml saline. Left-sided thoracotomy was
performed at the 4th or 5th intercostal space. The pericar-
dium was gently removed and the left anterior descending
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coronary artery (LAD) was permanently ligated caudal of
its origin with a 6–0 polypropylene suture. Ischemia was
conﬁrmed visually by discoloring and dyskinesia of the
myocardium. Following LAD ligation, 0.1ml ﬂuid was
injected by two-three injections into the border zone of the
discolored area. Animals received either saline 1× 106 ASCs
in saline or 1× 106 ASCs in alginate hydrogel. Sham animals
underwent the same procedure, with ligation in the myocar-
dium instead of the LAD. The thorax, muscle layers, and skin
were closed with 4-0 Vicryl sutures. The animals were treated
with 0.05mg/kg buprenorphine subcutaneously three times
daily, or orally two times daily, the following 72 hours.
2.8. Bioluminescence. D-Luciferin (SynChem, Germany) was
injected intraperitoneally in a dose of 30mg/kg at days 1, 3, 7,
and 14 days after the MI induction and treatment. In
addition, subsets of rats were scanned at day 21. Images were
acquired by IVIS® Lumina XR (Caliper Lifesciences,
PerkinElmer, USA) and Living Image® software v.4.3.1
(PerkinElmer, USA) with an exposure time of 3min, with
large binning and F-stop at F8. The optimal time for imaging
diﬀered according to how many cells were present in the
animal. For the ﬁrst week, the optimal time of acquisition
was 35min after injection, while it was 15min after 14
days, which could be explained by the hypoxic environment
and the oxygen dependent bioluminescence reaction. A
region of interest of similar size was used to collect the BLI
data as luminescence counts. Background from the animal
was subtracted from the data prior to analysis. BLI data were
analyzed as mean luminescence counts or luminescence as
percentage of day 1.
2.9. MRI. As with PET/CT scan, MRI was performed on
days 1, 14, and 28 after the MI induction. The animals
were sedated as mentioned during PET, and the scans
were performed using a preclinical 7 Tesla scanner (Bruker
Pharmascan, Bruker Medical, Germany) with horizontal
bore and a 60mm transmitter-receiver coil. Pilot scout
images (3 slices, 1mm thickness, ﬁeld of view 3.5× 3.5mm,
repetition time (TR) 85ms, echo time (TE) 1.5ms) were used
to validate positioning and to image the heart in 2- and 4-
chamber long axis images, as well as a perpendicular short
axis image. A stack of short axis cine-FLASH sequences was
acquired to cover the ventricle with 1mm thick slices and
0.5mm between slices. Cine-FLASH sequences were gated
on respiration and ECG, with a ﬁeld of view of 5.0× 5.0 cm,
matrix size of 256× 256, TR 4.8ms, and TE 2.0ms,
bandwidth 4566.7Hz, 150 repetitions, and ﬂip angle of 10°.
A multislice gated T1 FLASH sequence was used to visualize
the area of increased late gadolinium enhancement (LGE)
20min after IV administration of gadolinium contrast
(gadobutrol, 0.1mol/kg, Gadovist®, Bayer Scherring Pharma,
Germany). The T1 sequence used was 1mm slices with
0.5mm gab, ﬁeld of view 6× 6 cm, matrix size 256× 256, TR
70ms, TE 2.8ms, and ﬂip angle 30°.
Images were exported as DICOM and analyzed using
dedicated software (cvi42 versus 4.0.1, Circle Cardiovascular
Imaging, Canada). A total of 5–7 of the short axis cine images
were used for calculation of heart volumes: left ventricular
ejection fraction (LVEF), end-diastolic volume (EDV), end-
systolic volume (ESV), and myocardial mass. Slices of similar
location in the rat heart were used for analysis between acqui-
sition days. Systole and diastole was manually assessed from
the 15–20 frames for each slice. The endocardial and epicar-
dial contours were drawn manually on each viable slice for
the systole and diastole. For calculation of infarct area, the
guided automatic LGE mapping in cvi42 was used. The
infarcted area was deﬁned as deviating more than 2.5 stan-
dard deviations from the reference myocardium. The infarct
area at days 14 and 28 was deﬁned as the area which clearly
diﬀered in thickness from the regular myocardium, and
infarct thickness was measured as an average length of at
least ﬁve manual thickness measurements at diﬀerent loca-
tions across the infarct.
2.10. 82Rubidium-PET/CT Imaging. Rats were anesthetized
with 4% sevoﬂurane on days 1, 14, and 28 after the operation
for PET and MRI imaging. PET imaging was performed
using a dedicated preclinical PET/CT scanner (Siemens
Inveon, USA). After the dorsal vein cannulation by a perma-
nent 24G catheter, the rats were maintained on 0.5–4.0%
sevoﬂurane during the scans. The rats were placed on a water
heated bed in a prone position, with respiration and ECG
monitoring. Correct positioning was validated by initial CT
scout image. A 82Rb generator (CardioGen-82, Bracco Diag-
nostics Inc., USA), just expired for clinical use, was equipped
with a three-way valve, allowing control of the amount of
infusion to the rats [24], and calibrated according to
manufacturer’s recommendations. The animals received
approximately 30–150MBq 82Rb in 1.25–1.75ml saline
solution, shortly after a 10min list mode PET acquisition
was started. The animals were injected with 1.5ml CT con-
trast (Omnipaque 350mg, GE Healthcare, Denmark) just
before a CT scan was performed for anatomical reference
for attenuation correction. To minimize 82Rb activity from
the blood pool, the PET list mode data was histogrammed
into two time frames: the ﬁrst 45 sec and the remaining
555 sec. Subsequently, the images were reconstructed as
described previously [23].
PMOD cardiac tool version 3.3 (PMOD technologies
LLC, Switzerland) was used for processing and analysis of
the PET data. Initially, a fusion image of the PET and CT
was created to verify the placement of the heart for attenua-
tion correction. The PET images were then reoriented into
short, vertical, and horizontal long axis. The myocardial con-
tour was determined semiautomatically, by setting marker
guidance on basal and apical points of the left ventricle,
followed by visual inspection and possible correction. The
perfusion was quantiﬁed as local myocardial 82Rb activity
as percentage of maximum myocardial activity. These rela-
tive values were obtained in myocardial segments according
to the 17 American Heart Association (AHA) segments
[23] and as activity for the whole heart. Data were compared
between scans of the individual rat, before comparisons were
made between groups.
2.11. Histology. Immediately following animal sacriﬁce by
decapitation during anesthesia, the heart was excised, washed
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in saline, retrograde perfusion from the aorta was per-
formed with saline followed by 4% paraformaldehyde.
The heart was then placed in formaldehyde for 24 hours
and stored in 70% ethanol before embedding in paraﬃn.
The hearts were cut in the short axis on a microtome,
and immunohistochemistry was performed using the fol-
lowing: CD31 (Novus Bio, NB100-2284), CD68 (Abcam,
125212), Masson’s trichrome, and hematoxylin and eosin
(H&E). Prior to antibody staining, antigen retrieval was
performed using citrate buﬀer and microwave treatment.
Images were obtained by an ×20 objective scanning and
subsequent stitching, producing images of the entire short
axis slice. Fibrosis on Masson’s trichrome stainings was
quantiﬁed using ImageJ (Fiji) on the entire heart. CD31
clusters in peri-infarct regions were scored from 1–4, and
CD68 was counted in the whole infarct area and normalized
to the counted area.
2.12. Statistics. For functional measurements, changes in
measured parameters within groups were assessed using
paired t-test with Bonferroni correction, while comparisons
between groups were performed using univariate analysis
with day 1 as covariate and Tukey as post hoc test. Retention
was compared using repeated measures ANOVA with Tukey
post hoc test. All statistics were performed using SPSS (IBM
SPSS statistics v. 22).
3. Results
3.1. AMI Induction and Survival. A total of 97 animals
were included in this study, of which 37 did not survive
the AMI procedure. Other animals died or were eutha-
nized due to anesthesia during scanning (n = 8) or external
wound (n = 1). Rats weighted 266± 15 g at the time of the
procedure, 259± 17 g at day 1, 273± 16 g at day 14, and
300± 16 g at day 28.
A total of 51 rats completed the entire experimental
period. Not all MRI and PET images were of optimal quality,
and data from some rats could not be analyzed due to this.
For MR data, a total of 38 rats were available for analysis:
sham (n = 5), control (n = 9), ASCs in saline (n = 10), and
ASCs in alginate hydrogel (n = 13). For BLI data, a total of
38 rats were available for analysis: ASCs in saline (n = 18)
and ASCs in alginate hydrogel (n = 20). For perfusion
data, 19 rats were available for analysis: sham (n = 2), con-
trol (n = 6), ASCs in saline (n = 8), and ASCs in alginate
hydrogel (n = 3).
3.2. Eﬀect of Alginate Hydrogel on Cell Retention. There was
no signiﬁcant diﬀerence in BLI signal intensity or reten-
tion between the ASC treatment groups. ASCs in saline
generally produced a higher intensity BLI signal than
ASCs in alginate hydrogel (p = 0 36). In contrast, there
was a tendency for ASCs in alginate hydrogel to be better
retained (p = 0 42) (Figure 2).
3.3. Improved Functional Recovery in Treatment Groups.
LVEF increased signiﬁcantly in the follow-up period in
both of the treatment groups (ASCs in saline: from
42.6% to 50.3% at day 14, p < 0 05, and to 49.5% at day
28, p < 0 001; ASCs in alginate hydrogel: from 45.0% to
50.9% at day 14, p < 0 05, and to 50.8% at day 28, p <
0 001), whereas this was not the case in the control group
(from 42.6% to 43.2% at day 14, NS, and to 43.9% at day
28, NS) (Table 1 and Figure 3). When comparing the
change in LVEF between groups, the change was signiﬁ-
cant higher in the treatment groups compared with the
control group from day 1 to day 28 (ASCs in saline versus
controls: p < 0 01; ASCs in alginate hydrogel versus con-
trols: p < 0 05), but not from day 1 to day 14 (ASCs in
saline versus controls: p = 0 062; ASCs in alginate hydrogel
versus controls: p = 0 087). No diﬀerence in ΔLVEF was
observed between the ASC treatment groups (p > 0 8).
When excluding rats with smaller infarctions, deﬁned
by LVEF> 50% at day 1, the mean beneﬁt of the treatment
at day 28 was more pronounced, with ΔLVEF increased
from 6.7% to 7.2% and 5.7% to 8.0% for ASCs in saline
(p < 0 05) and alginate hydrogel (p < 0 01), respectively
(Table 1). No signiﬁcant diﬀerence was observed in ESV
between the groups (Table 1), and there was no diﬀerence
in LVEF or ESV between the two ASC cell lines used for
treatment (p = 0 56).
3.4. Infarct Size. The ratio between the infarct area at day 1
and the infarct area at day 28 was used as a measure of
myocardial infarct salvage. There was a tendency for greater
infarct salvage in the treatment groups compared with con-
trols, but this was not signiﬁcant (ASCs in saline: p = 0 46;
ASCs in alginate hydrogel: p = 0 24). The same was apparent
for infarct thickness (ASCs in saline: p = 0 83; ASCs in
alginate hydrogel: p = 0 58) (Figure 4).
3.5. Perfusion. 82Rb-PET/CT showed that the whole heart
perfusion in infarcted rats increased from day 1 to day
28 (controls and ASCs in saline: p < 0 05, ASCs in alginate
hydrogel: p = 0 149). The increase in whole heart perfusion
(in percentage points) at day 28 tended to be higher in the
treatment groups (ASCs in saline versus controls: p < 0 05,
ASCs in alginate hydrogel versus controls: p = 0 16). On a
segmental basis, there tended to be an increased apical
perfusion in the ASC treatment groups at day 28 com-
pared to the sham group (ASCs in saline: p = 0 043, ASCs
in alginate hydrogel: p = 0 057, controls: p = 0 157), but
there was no signiﬁcant diﬀerence between the treatment
groups and controls (p > 0 8 for both ASC treatment
groups) (Figure 5).
3.6. Histology. The infarct thickness measured on Masson’s
trichrome was controls: 655± 126μm, ASCs in saline: 730±
118μm, and ASCs in alginate hydrogel: 831± 404μm. There
was no diﬀerence in percentage of ﬁbrosis: controls: 33± 8,
ASCs in saline: 36± 17, and ASCs in alginate hydrogel:
31± 8%, p > 0 8 for both ASC treatment groups compared
with controls. More CD31-positive vessel clusters, as well
as large vessels in the infarct area, were detected in the
treatment groups, though not signiﬁcant. There was a non-
signiﬁcant tendency for less CD68+ cells in the infarcted
area in the treatment groups (control: 18± 12, ASCs in
saline: 10± 4, p = 0 35 versus controls, and ASCs in alginate
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hydrogel: 14± 3 CD68+ cells/mm2, p = 0 63 versus con-
trols). Sample images of each staining can be found in
supplementary Figure S1.
4. Discussion
4.1. Validation of Transduced Cells. In order to increase
external validation of the study, we used more than one
cell line. There was no diﬀerence in eﬃcacy or retention
between the cell lines. The L2T-transduced ASC cell lines
were able to triple diﬀerentiate and expressed common
ASC surface markers at a level comparable to regular
ASCs [25]. In addition, the cells did not show any signs
of senescence, which is in line with previously results from
our lab [26].
4.2. Retention. We did not observe an increase in cell reten-
tion using the alginate hydrogel for ASC administration,
compared to injection of ASCs in saline. A large animal study
with treatment of chronic infarctions also found no eﬀect
on MSC retention after two weeks using 1% alginate
hydrogel as in our study, but showed improved retention
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using 2% alginate hydrogel [27]. Others have found
increased retention using other hydrogels or formulations.
Yang et al. found improved retention of syngenic trans-
planted Sprague-Dawley ASCs using ﬁbrin hydrogel. They
found >20% increased BLI signal compared with saline at
day 14 after injection and BLI detection at day 28 only in
the ﬁbrin group [28]. Danoviz et al. showed an increased
retention with both ﬁbrin hydrogel and collagen hydrogel
24 hours after injection in rats [29].
4.3. Eﬀect of Cell Treatment on Myocardial Functional
Recovery. The improvements in LVEF from day 1 in the
ASC treatment groups were signiﬁcant already after 14 days,
though not signiﬁcantly increased compared to the control
group, due to fewer data points at day 14 than for day 28.
There is evidence that cell therapy is most eﬃcient with
large defects and lower LVEF [30–32]. Hence, we did a
subgroup analysis in the animals with LVEF lower than
50% at day 1, indicating small infarctions, which resulted
in more pronounced ASC treatment eﬀect after 28 days
(Table 1). The functional improvements are in line with
the results from recent meta-analyses for small and large
animal studies. These studies found MSC therapy for MI
to improve LVEF with 7.5% in mouse AMI and ~8% in
large animal MI [33–35].
4.4. Infarct Size and Perfusion Defect. For reports of positive
results of MSC therapy for rat AMI, in addition to increased
LVEF [36–40], researchers have found the treatment to
increase vessel density [36, 37, 39] and scar thickness [40],
while decreasing apoptosis [37, 39, 40], infarct size [36, 40],
and ﬁbrosis [36, 40]. These are usually observed using
histochemistry. In line with this, we observed a tendency of
increased scar thickness and decreased infarct area using
MRI and histology. However, we did not observe any change
in ﬁbrosis in response to ASC treatments. This could be.
Furthermore, we did observe a functional beneﬁt of the
treatment despite the lack of signiﬁcant evidence of increased
infarct thickness and decreased infarct size compared
with controls.
Table 1: Treatment eﬀect on left ventricular (LV) function by cardiac MRI.
Group Sham Control ASCs in saline ASCs in alginate hydrogel
LV function (LVEF and LVESV) by cardiac MRI
LVEF (%)
Day 1 60.84± 2.21 42.64± 11.66 42.60± 5.98 45.04± 9.08
Day 14 61.12± 0.94 43.24± 11.05 50.32± 4.34 50.91± 4.76
Day 28 61.08± 1.83 43.85± 10.68 49.48± 3.75 50.75± 7.28
ΔLVEF 14 days 0.28± 1.80 1.73± 4.90 6.99± 6.26 4.81± 4.89
ΔLVEF 28 days 0.24± 1.97 1.21± 3.77 6.89± 4.67 5.71± 4.48
LVESV (ml)
Day 1 0.12± 0.02 0.19± 0.04 0.17± 0.04 0.17± 0.05
Day 14 0.14± 0.04 0.23± 0.07 0.21± 0.06 0.17± 0.02
Day 28 0.16± 0.04 0.25± 0.07 0.22± 0.06 0.20± 0.05
ΔLVESV 14 days 0.02± 0.02 0.04± 0.04 0.05± 0.04 0.01± 0.02
ΔLVESV 28 days 0.04± 0.03 0.06± 0.05 0.05± 0.04 0.03± 0.02
Number of animals n = 5 n = 9 n = 10 n = 13
Data without LVEF> 50% at day 1 in infarct groups
LVEF (%)
Day 1 60.84± 2.21 36.62± 9.17 41.57± 5.32 41.07± 8.09
Day 14 61.12± 0.94 38.83± 8.80 49.13± 3.28 48.64± 4.02
Day 28 61.08± 1.83 38.34± 8.43 48.72± 3.06 49.08± 8.13
ΔLVEF 14 days 0.28± 1.80 2.21± 5.70 7.22± 6.83 7.79± 2.91
ΔLVEF 28 days 0.24± 1.97 1.71± 4.59 7.15± 4.87 8.02± 2.30
LVESV (ml)
Day 1 0.12± 0.02 0.21± 0.03 0.18± 0.04 0.19± 0.04
Day 14 0.14± 0.04 0.25± 0.03 0.22± 0.06 0.18± 0.02
Day 28 0.16± 0.04 0.28± 0.07 0.23± 0.05 0.22± 0.06
ΔLVESV 14 days 0.02± 0.02 0.04± 0.05 0.05± 0.05 0.00± 0.02
ΔLVESV 28 days 0.04± 0.03 0.07± 0.05 0.05± 0.04 0.03± 0.02
Number of animals n = 5 n = 6 n = 9 n = 9
ASC: adipose-derived stromal cells; LVEF: left ventricular ejection fraction; LVESV: left ventricular end-systolic volume.
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The perfusion defect diminished over time after day 1
post MI and tended to diminish more in the treatment
groups compared to the controls group, although not sig-
niﬁcant. This is in line with more frequent observations of
clusters of vessels in the peri-infarcted area in the treat-
ment groups (supplementary material), which has previ-
ously been observed with cell treatment for MI [41].
Perfusion for ASCs in alginate hydrogel was not signiﬁ-
cantly increased from baseline, and the change in perfu-
sion from day 1 to day 28 was not signiﬁcantly higher
than sham. This is due to the small number of animals
in this group (n = 3). This was due to technical challenges,
which coincidently occurred during the scans from the
alginate hydrogel group.
4.5. Retention and Functional Beneﬁt. Increased retention
and function have been found by Xia et al. with a
thermosensitive hydrogel, which increased retention of
allogeneic MSCs at 2 hours, day 1, and day 28 in a
mouse AMI model. The hydrogel group exhibited
increased capillary density and LVEF, as well as reduced
interstitial ﬁbrosis compared to the saline group. The
increase in LVEF compared to control groups was more
than doubled in the hydrogel group (~13% increase com-
pared with ~30% increase in the saline group and hydro-
gel group, resp.) [42]. Similarly, Lin et al. increased
retention of bone marrow mononuclear cell using self-
assembling peptide nanoﬁbers in a pig model of AMI.
As with Xia et al., the functional eﬀect of the treatment
in terms of increased LVEF was more than doubled by
the increase in retention [43].
The link between cell retention and functional beneﬁt
is mirrored in our study, with similar treatment eﬀect
and retention in the ASC treatment groups. The fact that
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Figure 3: Cardiac pump function. (a) Cine image analysis of hearts from each group in systole. Endocardial (red) and epicardial (green)
contours. Black arrow denotes papillary muscles in the sham group. (b) Results for left ventricular ejection fraction (LVEF) (total n = 38)
and (c) LVEF results when excluding rats with >50% LVEF at day 1 (total n = 29). ∗ denotes signiﬁcant diﬀerence from baseline
(∗p < 0 05; ∗∗p < 0 01). Inserted p values denote diﬀerence between ASC treatment groups and control group at day 28. ASC: adipose-
derived stromal cells.
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the alginate hydrogel did not signiﬁcantly increase ASC
retention could be because it is designed for intracoronary
injection following clinical AMI and not intramyocardial
administration [44].
5. Limitations
The fact that the ASCs were injected immediately after AMI
means that there is no functional measurement after the AMI
and before the treatment. If there was an eﬀect of the treat-
ment already after 24 hours, the results of functional beneﬁt
of the treatment would therefore be blunted.
We did not include a group with alginate hydrogel
without ASCs. There could be a functional eﬀect of applying
the alginate hydrogel without ASCs, but we did not investi-
gate this, since we were mainly interested in the potential
retention and function of the ASCs. Our results do not
suggest an independent eﬀect of the alginate hydrogel applied
by direct intramyocardial injection, though it has been shown
to protect against dilated cardiomyopathy, when applied via
the coronary arteries in a pig model of AMI [44].
The infarctions were not homogeneous, resulting in large
variations within the groups. This could obscure the ﬁnal
results. In an attempt to both show the full picture and
decrease the intragroup variation, we have presented results
with all data included, as well as data corrected for LVEF
above 50% at day 1.
The ﬁrst measurement of retention was for most animals
24 hours after administration. This is likely may indicate that
we are only measuring a fraction of the administered cells,
since only 10% of injected cells are retained 1 hour after
intramuscular injection [7]. However, other researchers have
found diﬀerences in retention using 24 hours as the ﬁrst BLI
time point and been able to correlate it with diﬀerences in
functional heart improvement [9, 28].
The 82Rb-PET/CT perfusion imaging is technically
challenging in small animal models, due to the combina-
tion of high positron range of the isotope and small
dimensions of the heart. In addition, imaging was only per-
formed at rest, providing data on the perfused area but not
coronary ﬂow reserve. However, this method has been shown
to correlate with wall motion measured by MRI in a rat AMI
model [24].
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Figure 4: Infarct size. (a) Analysis of infarct area using representative images. Black arrow annotates gadolinium-enhanced area 15 minutes
after IV injection at day 1. Grey arrow annotates clear thinning of the myocardium at day 28. The turquoise contour encircles the infarct area
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For both (b) and (c), n = 38.
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6. Conclusion
This study investigated for the ﬁrst time if administration of
human ASCs in a clinically translatable 1% alginate hydrogel
could increase the retention of the injected cells and if this
would aﬀect the regenerative eﬀect of the treatment in a rat
AMI model. We found no signiﬁcant eﬀect on retention of
the coadministration. Administration of human ASCs in
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alginate hydrogel increased pump function signiﬁcantly
when compared to nontreated AMI, but only to a level
comparable to ASC treatment without alginate hydrogel.
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